Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

5
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
5
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Long-term Potentiation01:25

Long-term Potentiation

2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
2.7K
Long-term Potentiation01:35

Long-term Potentiation

51.4K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
51.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Frontiers in immunology·2026
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Should natalizumab be used despite JC virus positivity? No.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.

Neurology and therapy·2025
Same author

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

Journal of neurology, neurosurgery, and psychiatry·2024
Same author

Assessing disease progression and treatment response in progressive multiple sclerosis.

Nature reviews. Neurology·2024

Related Experiment Video

Updated: Apr 21, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K

[Fampridine and multiple sclerosis].

Henrik Kahr Mathiesen1, Per Soelberg Sørensen

  • 1Neurologisk Klinik, Dansk Multipel Sklerose Center, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. hkm@rh.dk.

Ugeskrift for Laeger
|October 28, 2014
PubMed
Summary
This summary is machine-generated.

Fampridine can improve walking in multiple sclerosis patients. This review covers its use, including who should and shouldn't take it, potential side effects, and recommendations for Danish patients.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

16.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

16.2K

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • Multiple sclerosis (MS) is a chronic neurological disease.
  • Fampridine is a medication used to manage MS symptoms.

Purpose:

  • To review the background, indications, contraindications, side effects, and recommendations for fampridine use in Danish multiple sclerosis patients.

Summary:

  • This review synthesizes current knowledge on fampridine for multiple sclerosis.
  • It details the drug's profile, including patient selection and adverse events.
  • Specific recommendations for the Danish healthcare context are provided.

Impact:

  • Aims to guide clinicians in the safe and effective prescription of fampridine.
  • Enhances patient care by providing evidence-based information.
  • Contributes to the understanding of fampridine's role in multiple sclerosis management in Denmark.